Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 3;30(9):8159-8171.
doi: 10.3390/curroncol30090592.

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review

Caitlin Lazurko  1 , Revital Linder  2 , Kate Pulman  3 , Genevieve Lennox  3 , Tomer Feigenberg  3 , Rouhi Fazelzad  4 , Taymaa May  5 , Tiffany Zigras  3
Affiliations

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review

Caitlin Lazurko et al. Curr Oncol. .

Abstract

Serous epithelial ovarian cancer, classified as either high-grade (90%) or low-grade (10%), varies in molecular, histological, and clinicopathological presentation. Low-grade serous ovarian cancer (LGSOC) is a rare histologic subtype that lacks disease-specific evidence-based treatment regimens. However, LGSOC is relatively chemo-resistant and has a poor response to traditional treatments. Alternative treatments, including biologic therapies such as bevacizumab, have shown some activity in LGSOC. Thus, the objective of this systematic review is to determine the effect and safety of bevacizumab in the treatment of LGSOC. Following PRISMA guidelines, Medline ALL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Embase all from the OvidSP platform, ClinicalTrials.gov, International Clinical Trials Registry Platform, International Standard Randomised Controlled Trial Number Registry were searched from inception to February 2022. Articles describing bevacizumab use in patients with LGSOC were included. Article screening, data extraction, and critical appraisal of included studies were completed by two independent reviewers. The effect of bevacizumab on the overall response rate, progression-free survival, overall survival, and adverse effects were summarized. The literature search identified 3064 articles, 6 of which were included in this study. A total of 153 patients were analyzed; the majority had stage IIIC cancer (56.2%). The overall median response rate reported in the studies was 47.5%. Overall, bevacizumab is a promising treatment for LGSOC, with response rates higher than traditional treatment modalities such as conventional chemotherapy, and is often overlooked as a treatment tool. A prospective clinical trial evaluating the use of bevacizumab in LGSOC is necessary to provide greater evidence and support these findings.

Keywords: bevacizumab; low-grade serous ovarian cancer; overall response rate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA diagram.
See this image and copyright information in PMC

References

    1. Malpica A., Deavers M.T., Lu K., Bodurka D.C., Atkinson E.N., Gershenson D.M., Silva E.G. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 2004;28:496–504. doi: 10.1097/00000478-200404000-00009. - DOI - PubMed
    1. Meinhold-Heerlein I., Fotopoulou C., Harter P., Kurzeder C., Mustea A., Wimberger P., Hauptmann S., Sehouli J. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch. Gynecol. Obstet. 2016;293:695–700. doi: 10.1007/s00404-016-4035-8. - DOI - PubMed
    1. Bodurka D.C., Deavers M.T., Tian C., Sun C.C., Malpica A., Coleman R.L., Lu K.H., Sood A.K., Birrer M.J., Ozols R., et al. Reclassification of serous ovarian carcinoma by a 2-tier system: A gynecologic oncology group study. Cancer. 2012;118:3087–3094. doi: 10.1002/cncr.26618. - DOI - PMC - PubMed
    1. Vang R., Shih I.-M., Kurman R.J. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv. Anat. Pathol. 2009;16:267–282. doi: 10.1097/PAP.0b013e3181b4fffa. - DOI - PMC - PubMed
    1. Gershenson D.M., Sun C.C., Iyer R.B., Malpica A.L., Kavanagh J.J., Bodurka D.C., Schmeler K., Deavers M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 2012;125:661–666. doi: 10.1016/j.ygyno.2012.02.037. - DOI - PMC - PubMed

Publication types

MeSH terms